Peptide therapy creates a premium, recurring revenue stream
Candidates must be screened for thyroid cancer risk, pancreatitis history, gallbladder and kidney disease, and mental health history before starting
Here's what you should know going in: Commonly reported effects include nausea, vomiting, diarrhea, and constipation, particularly during initial dose escalation Warnings and precautions in the prescribing information for applicable semaglutide and tirzepatide products cover pancreatitis, gallbladder disease, and kidney injury associated with volume depletion If you're on insulin or sulfonylureas, discuss hypoglycemia risk with your prescriber - GLP-1 medications can affect blood sugar control when combined with those drugs These medications slow gastric emptying, which can affect how orally taken medications are absorbed - worth flagging if you take other oral drugs regularly Certain FDA-approved semaglutide and tirzepatide products carry a boxed warning concerning thyroid C-cell tumors observed in rodents
Genetic variants can alter peptide receptor expression or peptide breakdown, so two people on the same protocol may see different results
